DB-1303/BNT323 + Capecitabine + Paclitaxel + Nab-paclitaxel
Phase 3Active 0 views this week 0 watching⚡ Active
Interest: 41/100
41
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Breast Cancer
Conditions
Metastatic Breast Cancer
Trial Timeline
Jan 18, 2024 → Jul 1, 2028
NCT ID
NCT06018337About DB-1303/BNT323 + Capecitabine + Paclitaxel + Nab-paclitaxel
DB-1303/BNT323 + Capecitabine + Paclitaxel + Nab-paclitaxel is a phase 3 stage product being developed by BioNTech for Metastatic Breast Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06018337. Target conditions include Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Breast Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
17
Activity
12
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06018337 | Phase 3 | Active |
Competing Products
20 competing products in Metastatic Breast Cancer